Deprecated: Array and string offset access syntax with curly braces is deprecated in /var/www/wp-content/plugins/gravityforms/common.php on line 4151
Investor Announcement Archives - Page 3 of 20 - Alterity Therapeutics
Hit enter to search or ESC to close

Category: Investor Announcement

Chairman’s Address 2021 Annual General Meeting

I am pleased to present my Chairman’s address at this year’s Annual General Meeting. For the second year in a row, we do this under unique circumstances, and we appreciate the involvement of our shareholders and our corporate partners in today’s virtual setting. FY 21 was a significant year for Alterity and for me personally ...

Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced a poster presentation and accompanying video were delivered at the American Autonomic Society 32nd Annual Internation Symposium on the Autonomic Nervous System. The poster, entitled, Cardiovascular safety and pharmacokinetics of ATH434, ...
Senior male researcher carrying out scientific research

Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases

Colorectal impairment reversed in a preclinical model of Parkinson’s Disease   ATH434 presents a novel mechanism of action for the treatment of neurodegenerative diseases Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the publication of two preclinical studies demonstrating ...

Appendix 4C – Q1 FY22 Quarterly Cash Flow Report

Highlights: New details on ATH34 Phase 2 clinical trial released. Data from bioMUSE presented at International Parkinson and Movement Disorder Society Congress. Expanded intellectual property portfolio positions future opportunities. Cash balance as of 30 September 2021 of A$41.3M. Quarterly operating cash outflow of $4.9M as expected and in-line with clinical trial activity. Alterity Therapeutics Limited ...

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

– Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) – – Expanding bioMUSE Natural History Study – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced an expansion of the clinical development program for the Company’s lead ...

Presentation of New Biomarker Data at Scientific Congress

Study Results Successfully Inform the Design of ATH434 Phase 2 Clinical Trial Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that data was presented from the Company’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) study at the International ...

Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s

Composition of Matter Patent Covers More than 80 Novel Compounds Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the United States Patent and Trademark Office  (USPTO) has issued a Notice of Allowance for Alterity’s patent application No. 17/239,375. The composition ...

Quarterly Cash Flow Report

Highlights: Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial Publication in Movement Disorders demonstrates that ATH434 reduces α-synuclein related neurodegeneration in MSA animal model Presents to MST Access Australian Micro & Small Caps Conference Cash balance at 30 June 2021 of A$28M Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or ...